It is health that is real wealth
and not pieces of gold and silver

- Mahatma Gandhi

Newborn Screening ACT Sheet

[Decreased C0 and other Acylcarnitines]
Carnitine uptake Defect (CUD)

Differential Diagnosis: Carnitine uptake defect (CUD), maternal carnitine deficiency and prematurity.

Condition Description: CUD is caused by a defect in the carnitine transporter that moves carnitine across the plasma membrane. Reduced carnitine limits acylcarnitine formation preventing transport of long-chain fatty acids into mitochondria, thereby limiting energy production. Tissues with high energy needs (skeletal and heart muscle) are particularly affected.


  • Contact family to inform them of the newborn screening result and ascertain clinical status (poor feeding, lethargy, tachypnea).
  • Consult with pediatric metabolic specialist.
  • Evaluate the newborn (tachycardia, hepatomegaly, reduced muscle tone); initiate emergency treatment as indicated by metabolic specialist.
  • Initiate timely confirmatory/diagnostic testing as recommended by specialist.
  • Educate family about signs, symptoms, and need for urgent treatment if infant becomes ill.
  • Report findings to newborn screening program.

Diagnostic Evaluation:

Plasma carnitine analysis will reveal decreased free and total carnitine (C0) in plasma in an affected infant. If the total and free carnitine are normal in the infant, it may suggest a maternal carnitine deficiency and plasma carnitine analysis in the mother is indicated. Transporter assays in fibroblasts and SLC22A5 (OCTN2 carnitine transporter) gene sequencing establish the diagnosis. Prematurity should be considered in the differential diagnosis.

Clinical Considerations:

Carnitine transporter defect has a variable expression and variable age of onset. Characteristic manifestations include lethargy, hypotonia, hepatomegaly, and cardiac decompensation due to cardiomyopathy. Hypoglycemia is typical in acute episodes. These are rarely present in the neonatal period.

How can we help you